Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 4/20 | 0.63 |
| ▸ | RAMP3 | O60896 | 8/20 | 0.62 |
| ▸ | CALCR | P30988 | 8/20 | 0.62 |
| ▸ | NPY2R | P49146 | 7/20 | 0.61 |
| ▸ | NPY4R | P50391 | 7/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.61 |
| ▸ | NPY1R | P25929 | 5/20 | 0.61 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30364495 | 0.97 | TFPI (0.68) | TFPIRAMP3CALCRNPY2RNPY4R | |
| SCHEMBL30872190 | 0.96 | CXCR4 (0.64) | TFPIRAMP3CALCRNPY2RNPY4R | |
| SCHEMBL31418387 | 0.92 | TFPI (0.63) | TFPIRAMP3CALCRNPY2RNPY4R | |
| SCHEMBL29615082 | 0.88 | CALCR (0.61) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| Melectin SCHEMBL30448502 | 0.86 | REN (0.62) | TFPI | |
| SCHEMBL29358935 | 0.84 | TFPI (0.64) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30422242 | 0.83 | CALCR (0.56) | RAMP3CALCR | |
| SCHEMBL29843115 | 0.82 | REN (0.58) | — | |
| SCHEMBL30277958 | 0.82 | NPY2R (0.62) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL29724165 | 0.81 | CXCR4 (0.60) | TFPIRAMP3CALCRNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288656-A1 | APPLICATION OF CAERIN 1.1/1.9 COMBINED WITH ANTI-CD47 ANTIBODY IN PREPARING DRUG FOR TREATING MELANOMA | WNL BIOMED TECH PTY. LTD. (AU) | 2025-09-18 | — | — | US | claimed |
| US-12377186-B2 | Antimicrobial biopolymer compositions, methods of synthesis, and applications of use | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-08-05 | — | — | US | claimed |
| CN-118634315-A | Application of polypeptide in preparation of anti-porcine reproductive and respiratory syndrome virus products | 华中农业大学 | 2024-09-13 | — | — | CN | claimed |
| WO-2024109339-A1 | USE OF CAERIN1.1/1.9 COMBINED WITH ANTI-CD47 ANTIBODY IN PREPARATION OF DRUG FOR TREATMENT OF MELANOMA | 中奥生物医药技术(广东)有限公司 | 2024-05-30 | — | — | WO | claimed |
| CN-114395026-B | Broad-spectrum antibacterial peptide constructed based on rational design strategy | 福州大学 | 2023-11-21 | — | — | CN | claimed |
| WO-2023142449-A1 | BROAD-SPECTRUM ANTIBACTERIAL PEPTIDE CONSTRUCTED ON BASIS OF RATIONAL DESIGN STRATEGY | 福州大学 | 2023-08-03 | — | — | WO | claimed |
| CN-115969960-A | Application of Caerin1.1/1.9 peptide in preparation of drugs for inhibiting/treating bacterial biofilm growth | 中奥生物医药技术(广东)有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-115957306-A | Application of Caerin1.1/1.9 combined anti-CD47 antibody in preparation of drugs for treating melanoma | 中奥生物医药技术(广东)有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-114395026-A | Broad-spectrum antibacterial peptide constructed based on rational design strategy | 福州大学 | 2022-04-26 | — | — | CN | claimed |
| US-20250288656-A1 | APPLICATION OF CAERIN 1.1/1.9 COMBINED WITH ANTI-CD47 ANTIBODY IN PREPARING DRUG FOR TREATING MELANOMA | WNL BIOMED TECH PTY. LTD. (AU) | 2025-09-18 | — | — | US | disclosed |
| US-20250288656-A1 | APPLICATION OF CAERIN 1.1/1.9 COMBINED WITH ANTI-CD47 ANTIBODY IN PREPARING DRUG FOR TREATING MELANOMA | WNL BIOMED TECH PTY. LTD. (AU) | 2025-09-18 | — | — | US | disclosed |
| US-20250288656-A1 | APPLICATION OF CAERIN 1.1/1.9 COMBINED WITH ANTI-CD47 ANTIBODY IN PREPARING DRUG FOR TREATING MELANOMA | WNL BIOMED TECH PTY. LTD. (AU) | 2025-09-18 | — | — | US | disclosed |
| US-12377186-B2 | Antimicrobial biopolymer compositions, methods of synthesis, and applications of use | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-08-05 | — | — | US | disclosed |
| US-12281205-B2 | Modified antibacterial compositions and methods | THE UNIVERSITY OF MELBOURNE (AU) | 2025-04-22 | — | — | US | disclosed |
| CN-115969960-A | Application of Caerin1.1/1.9 peptide in preparation of drugs for inhibiting/treating bacterial biofilm growth | 中奥生物医药技术(广东)有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115957306-A | Application of Caerin1.1/1.9 combined anti-CD47 antibody in preparation of drugs for treating melanoma | 中奥生物医药技术(广东)有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-115957306-A | Application of Caerin1.1/1.9 combined anti-CD47 antibody in preparation of drugs for treating melanoma | 中奥生物医药技术(广东)有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-115957306-A | Application of Caerin1.1/1.9 combined anti-CD47 antibody in preparation of drugs for treating melanoma | 中奥生物医药技术(广东)有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-114395026-A | Broad-spectrum antibacterial peptide constructed based on rational design strategy | 福州大学 | 2022-04-26 | — | — | CN | disclosed |
| CN-114395026-A | Broad-spectrum antibacterial peptide constructed based on rational design strategy | 福州大学 | 2022-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281205-B2 | Modified antibacterial compositions and methods | TUFM, CLPTM1, MRPL21 | TFPI 4134/4885RAMP3 3792/4885CALCR 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.